{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:26Z","timestamp":1753877666816,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Breast cancer presents unique complexities for transgender individuals. This retrospective study characterized breast cancers in 14 transgender and nonbinary patients treated at a specialized transgender health center from 2016 to 2023. Patients with a median age of 53 (31\u201365 years) were identified using international classification of disease-10 codes. Most (86%) were aged 40 or older and eligible for screening mammography. The cohort included 6 trans men, 7 trans women, and one genderqueer individual. Diagnoses included ductal carcinoma in situ (36%), lobular carcinoma in situ (7%), stage 1 (29%), stage 2 (21%), and breast implant-associated anaplastic large cell lymphoma (7%). Screening mammography diagnosed 29%, 43% presented with a mass, and 29% were detected during pre-surgical imaging. Half had estrogen-based gender-affirming hormone therapy (GAHT) and half testosterone-based, with mean GAHT durations of 16.6 years. Biomarker profiles revealed 67% estrogen receptor (ER)-positive and 33% ER-negative cancers. This study highlights underutilized screening mammography and diverse cancer subtypes in this underserved population.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf087","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:05Z","timestamp":1748345825000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of transgender patients with breast cancer: a single institution experience"],"prefix":"10.1093","volume":"30","author":[{"given":"Ethan","family":"Ravetch","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Breast Surgery, Montefiore Medical Center, Montefiore Breast Care Center , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9091-1927","authenticated-orcid":false,"given":"Nithya","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Weltz","sequence":"additional","affiliation":[{"name":"Dubin Breast Center at Mount Sinai , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D","family":"Safer","sequence":"additional","affiliation":[{"name":"Center for Transgender Medicine and Surgery, Mount Sinai Health System , New York, NY ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025052707365596900_CIT0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amepre.2017.11.009","article-title":"Gender identity disparities in cancer screening behaviors","volume":"54","author":"Tabaac","year":"2018","journal-title":"Am J Prev Med"},{"author":"International Classification of Diseases (ICD) for oncology","key":"2025052707365596900_CIT0002"},{"key":"2025052707365596900_CIT0003","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1055\/s-0037-1606103","article-title":"Breast cancer screening, management, and a review of case study literature in transgender populations","volume":"35","author":"Deutsch","year":"2017","journal-title":"Semin Reprod Med"},{"key":"2025052707365596900_CIT0004","doi-asserted-by":"publisher","first-page":"S502","DOI":"10.1016\/j.jacr.2021.09.005","article-title":"ACR appropriateness criteria\u00ae transgender breast cancer screening","volume":"18","author":"Brown","year":"2021","journal-title":"J Am Coll Radiol"},{"key":"2025052707365596900_CIT0005","doi-asserted-by":"publisher","first-page":"NP83","DOI":"10.1093\/asj\/sjx098","article-title":"Breast implant-associated anaplastic large-cell lymphoma in a transgender woman","volume":"37","author":"De Boer","year":"2017","journal-title":"Aesthet Surg J"},{"key":"2025052707365596900_CIT0006","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ejso.2018.06.035","article-title":"Breast cancer in transgender patients: a systematic review. Part 1: male to female","volume":"44","author":"Hartley","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2025052707365596900_CIT0007","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ejso.2018.06.021","article-title":"Breast cancer in transgender patients: a systematic review. Part 2: female to male","volume":"44","author":"Stone","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2025052707365596900_CIT0008","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.breast.2021.03.007","article-title":"Frequency and outcomes of benign breast biopsies in trans women: a nationwide cohort study","volume":"57","author":"de Blok","year":"2021","journal-title":"Breast"},{"key":"2025052707365596900_CIT0009","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgender Health"},{"key":"2025052707365596900_CIT0010","doi-asserted-by":"publisher","first-page":"351","DOI":"10.15585\/mmwr.mm7315e1","article-title":"Vital signs: mammography use and association with social determinants of health and health-related social needs among women\u2014United States, 2022","volume":"73","author":"Miller","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf087\/63370826\/oyaf087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf087\/63370826\/oyaf087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:06Z","timestamp":1748345826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf087\/8151384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf087","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf087"}}